JOP20210216A1 - علاج السرطان - Google Patents
علاج السرطانInfo
- Publication number
- JOP20210216A1 JOP20210216A1 JOP/2021/0216A JOP20210216A JOP20210216A1 JO P20210216 A1 JOP20210216 A1 JO P20210216A1 JO P20210216 A JOP20210216 A JO P20210216A JO P20210216 A1 JOP20210216 A1 JO P20210216A1
- Authority
- JO
- Jordan
- Prior art keywords
- cancer treatment
- cancer
- treatment
- erdafitinib
- provides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
يوفر الاختراع الحالي طريقة لعلاج السرطان باستخدام إردافيتينيب في المرضى المعرضين لخطر شديد.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19156806 | 2019-02-12 | ||
EP19176575 | 2019-05-24 | ||
PCT/EP2020/053490 WO2020165181A1 (en) | 2019-02-12 | 2020-02-11 | Cancer treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20210216A1 true JOP20210216A1 (ar) | 2023-01-30 |
Family
ID=69467563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2021/0216A JOP20210216A1 (ar) | 2019-02-12 | 2020-02-11 | علاج السرطان |
Country Status (15)
Country | Link |
---|---|
US (1) | US20220168298A1 (ar) |
EP (1) | EP3923942A1 (ar) |
JP (1) | JP2022521173A (ar) |
KR (1) | KR20210126654A (ar) |
CN (1) | CN113423402A (ar) |
AU (1) | AU2020223467A1 (ar) |
BR (1) | BR112021015686A2 (ar) |
CA (1) | CA3126959A1 (ar) |
IL (1) | IL285466A (ar) |
JO (1) | JOP20210216A1 (ar) |
MA (1) | MA54932A (ar) |
MX (1) | MX2021009670A (ar) |
SG (1) | SG11202107850VA (ar) |
TW (1) | TW202045173A (ar) |
WO (1) | WO2020165181A1 (ar) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2021396397A1 (en) * | 2020-12-11 | 2023-07-27 | Erasca, Inc. | Combination therapies for the treatment of cancer |
CN112957368A (zh) * | 2021-04-02 | 2021-06-15 | 南昌大学 | 一种司维拉姆的新用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3365335B1 (en) * | 2015-10-23 | 2024-02-14 | Array Biopharma, Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases |
TWI798199B (zh) * | 2017-02-06 | 2023-04-11 | 比利時商健生藥品公司 | 癌症治療 |
JOP20190280A1 (ar) * | 2017-06-02 | 2019-12-02 | Janssen Pharmaceutica Nv | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية |
-
2020
- 2020-02-11 KR KR1020217028671A patent/KR20210126654A/ko active Search and Examination
- 2020-02-11 US US17/430,025 patent/US20220168298A1/en active Pending
- 2020-02-11 CA CA3126959A patent/CA3126959A1/en active Pending
- 2020-02-11 SG SG11202107850VA patent/SG11202107850VA/en unknown
- 2020-02-11 JO JOP/2021/0216A patent/JOP20210216A1/ar unknown
- 2020-02-11 MX MX2021009670A patent/MX2021009670A/es unknown
- 2020-02-11 WO PCT/EP2020/053490 patent/WO2020165181A1/en unknown
- 2020-02-11 EP EP20703477.8A patent/EP3923942A1/en active Pending
- 2020-02-11 MA MA054932A patent/MA54932A/fr unknown
- 2020-02-11 AU AU2020223467A patent/AU2020223467A1/en active Pending
- 2020-02-11 CN CN202080013784.5A patent/CN113423402A/zh active Pending
- 2020-02-11 JP JP2021547154A patent/JP2022521173A/ja active Pending
- 2020-02-11 BR BR112021015686-0A patent/BR112021015686A2/pt unknown
- 2020-02-12 TW TW109104389A patent/TW202045173A/zh unknown
-
2021
- 2021-08-09 IL IL285466A patent/IL285466A/en unknown
Also Published As
Publication number | Publication date |
---|---|
SG11202107850VA (en) | 2021-08-30 |
EP3923942A1 (en) | 2021-12-22 |
AU2020223467A1 (en) | 2021-08-05 |
WO2020165181A1 (en) | 2020-08-20 |
IL285466A (en) | 2021-09-30 |
CA3126959A1 (en) | 2020-08-20 |
KR20210126654A (ko) | 2021-10-20 |
MX2021009670A (es) | 2021-09-08 |
CN113423402A (zh) | 2021-09-21 |
US20220168298A1 (en) | 2022-06-02 |
BR112021015686A2 (pt) | 2021-10-26 |
JP2022521173A (ja) | 2022-04-06 |
TW202045173A (zh) | 2020-12-16 |
MA54932A (fr) | 2021-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018022668A3 (en) | NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER | |
EP3867410A4 (en) | METHODS OF DETERMINING A TREATMENT FOR CANCER PATIENTS | |
MX2022008868A (es) | Tratamiento del cancer con tg02. | |
MX2020013808A (es) | Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer. | |
AU2015249633A8 (en) | Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab | |
WO2018136617A3 (en) | Bacteria for treating cancer | |
EA201991818A1 (ru) | Лечение рака | |
GB201903546D0 (en) | Cancer treatment | |
MX2020008195A (es) | Compuestos para el tratamiento del dolor. | |
EP4353320A3 (en) | Blood plasma and plasma fractions as therapy for tumor growth and progression | |
TN2019000211A1 (en) | Antitumoral compounds | |
ZA202206743B (en) | Therapy for the treatment of cancer | |
MX2017016114A (es) | Metodos para tratar o prevenir una proteopatia. | |
PH12020551080A1 (en) | Combination therapy for treating or preventing cancer | |
SG11202103141YA (en) | Combination therapy for the treatment of cancer | |
IL287652A (en) | Cancer treatment | |
IL281439A (en) | Combined treatment for blood cancer | |
IL284162A (en) | Integrated healing for cancer treatment | |
MX2022007955A (es) | Regimenes de dosificacion de erdafitinib. | |
MX2021009670A (es) | Tratamiento para el cancer. | |
JO3541B1 (ar) | علاجات طبية قائمة على اناموريلين | |
MX2017016346A (es) | Metodos de tratamiento con taselisib. | |
MX2020012964A (es) | Metodos para el tratamiento de cancer de vejiga. | |
MX2020012782A (es) | Inhibidor de ccr5 para el uso en el tratamiento de cancer. | |
IL288035A (en) | Cancer treatment |